# Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.

> **NCT06342544** · PHASE3 · RECRUITING · sponsor: **Fondation Ophtalmologique Adolphe de Rothschild** · enrollment: 128 (estimated)

## Conditions studied

- Ocular Myasthenia Gravis

## Interventions

- **DRUG:** immediate treatment with corticosteroids
- **DRUG:** addition of rituximab if recurrence

## Key facts

- **NCT ID:** NCT06342544
- **Lead sponsor:** Fondation Ophtalmologique Adolphe de Rothschild
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-29
- **Primary completion:** 2028-06
- **Final completion:** 2029-06
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06342544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06342544, "Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06342544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*